Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

NCT03659916 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Familial Intrahepatic Cholestasis

Interventions

DRUG: A4250 (odevixibat)

Sponsor

Albireo, an Ipsen Company